Veracyte (VCYT) came out with quarterly earnings of $0.19 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to loss of $0.03 per share a year ago.
In this ROBO Global Artificial Intelligence Index spotlight, we focus on Veracyte (VCYT). The index underlies the $137 million ROBO Global Artificial Intelligence ETF (THNQ).
Veracyte looks poised to deliver robust performance owing to its progress with key drivers and the strength in its diagnostics tests.
Veracyte (VCYT) reported earnings 30 days ago. What's next for the stock?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
After reaching an important support level, Veracyte, Inc. (VCYT) could be a good stock pick from a technical perspective. VCYT recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Veracyte (VCYT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Veracyte's (VCYT) second-quarter 2024 performance reflects the strength of its testing business.
On Tuesday, Veracyte, Inc VCYT reported second-quarter sales of $114.43 million, up 27% year over year, beating the consensus of $100.3 million.
Veracyte, Inc. (NASDAQ:VCYT ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Shayla Gorman – Senior Director, Investor Relations Marc Stapley – Chief Executive Officer Rebecca Chambers – Chief Financial Officer Conference Call Participants Mason Carrico – Stephens, Inc. Yuko Oku – Morgan Stanley Maggie Boeye – William Blair Joseph Conway – Needham & Company Prashant Kota – Goldman Sachs Thomas DeBourcy – Nephron Research Operator Good day and thank you for standing by. Welcome to the Veracyte Second Quarter 2024 Financial Results Call.
Veracyte (VCYT) came out with quarterly earnings of $0.30 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to loss of $0.12 per share a year ago.